Waltham, MA 4/4/16—Bioprocessing product firm Repligen has acquired Atoll, based in Weingarten, Germany, for $22.5 million, including $9.1 million in cash, from UV-Cap. Atoll provides the MediaScout family of prepacked chromatography columns for process development and clinical manufacturing of biologic drugs. Repligen stated that the acquisition expands its prepacked column LC product line into high-throughput process-development screening. The purchase is expected to add $3.0–$3.5 million to Repligen’s remaining nine-month revenues. “This acquisition extends our reach into the screening and process development labs where single-use platform technologies are evaluated and adopted,” stated Repligen President and CEO Tony J. Hunt. “As we look to the future, we see the Weingarten facility as our European commercial and manufacturing center for many of our high-value and flexible solutions for the bioprocessing industry.”